Skip to main content
Premium Trial:

Request an Annual Quote

Genetic Technologies Adds FedMed to PPOs Covering BrevaGen

NEW YORK (GenomeWeb News) – Genetic Technologies today said that its wholly owned subsidiary Phenogen Sciences has executed an agreement with preferred provider organization FedMed for access to its network of clinicians and healthcare providers.

The deal is the seventh between GTG and a US PPO, the Australian developer of the BrevaGen breast cancer risk assessment test, said. Last month, it signed agreements with MultiPlan and the Three Rivers Provider Network, and in total, the number of covered lives with access to BrevaGen as an in-network service is more than 102 million, GTG said.

Based in Rockville, Md., FedMed covers more than 40 million lives and has a network of more than 550,000 physicians, 60,000 ancillary care providers, and 4,000 hospitals nationwide. Phenogen is based in Charlotte, NC.

Financial and other terms of the deal were not disclosed.

The Scan

Pig Organ Transplants Considered

The Wall Street Journal reports that the US Food and Drug Administration may soon allow clinical trials that involve transplanting pig organs into humans.

'Poo-Bank' Proposal

Harvard Medical School researchers suggest people should bank stool samples when they are young to transplant when they later develop age-related diseases.

Spurred to Develop Again

New Scientist reports that researchers may have uncovered why about 60 percent of in vitro fertilization embryos stop developing.

Science Papers Examine Breast Milk Cell Populations, Cerebral Cortex Cellular Diversity, Micronesia Population History

In Science this week: unique cell populations found within breast milk, 100 transcriptionally distinct cell populations uncovered in the cerebral cortex, and more.